{"id":"W4406087364","doi":"10.1007/s40257-024-00909-5","title":"A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"Incyte","keywords":"Medicine; Ruxolitinib; Adverse effect; Atopic dermatitis; Tolerability; Janus kinase inhibitor; Eczema Area and Severity Index; Internal medicine; Clinical endpoint; Quality of life (healthcare); Pharmacokinetics; Body surface area; Clinical trial; Tofacitinib; Dermatology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003503777,0.0001870859,0.001888932,0.0004312157,0.0000295065,0.00001263909,0.0002432599,0.0001608168,0.00004242243],"category_scores_gemma":[0.001434857,0.0001512219,0.0003087136,0.000500934,0.0006836926,0.0001243715,0.00006125125,0.0005584721,0.00000859482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002110178,"about_ca_system_score_gemma":0.0006758386,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008876336,"about_ca_topic_score_gemma":0.00004956049,"domain_scores_codex":[0.9965345,0.0007143317,0.001942134,0.0002393047,0.0002378741,0.0003318463],"domain_scores_gemma":[0.9971247,0.001229552,0.0007892913,0.000339618,0.0002062481,0.0003105473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02459452,0.001334026,0.9570202,0.0000364458,0.0004283354,0.001334081,0.0001125918,0.00003004803,0.000001528021,0.0002017891,0.005364492,0.009541907],"study_design_scores_gemma":[0.0436401,0.001597816,0.9468485,0.0003269555,0.0002701615,0.00531942,0.0001465718,0.00001833495,0.00005544859,0.0005293412,0.001116871,0.000130441],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932933,0.0001131274,0.0003065413,0.005249368,0.000214374,0.000426506,0.00001216461,0.00001438398,0.0003701633],"genre_scores_gemma":[0.9910231,0.0001394134,0.002115115,0.006563306,0.00006478401,0.00001092905,0.000007117199,0.00001561609,0.00006060335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01904558,"threshold_uncertainty_score":0.6166651,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01936643116546527,"score_gpt":0.3473711334280457,"score_spread":0.3280047022625804,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}